Novel monoclonal antibodies against microcystin and their protective activity for hepatotoxicity
✍ Scribed by Satoshi Nagata; Hiroshi Soutome; Tomoaki Tsutsumi; Akihiro Hasegawa; Masaru Sekijima; Masao Sugamata; Ken-Ichi Harada; Masami Suganuma; Prof. Yoshio Ueno
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 931 KB
- Volume
- 3
- Category
- Article
- ISSN
- 1056-9014
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Six monoclonal antibodies (MAbs) to microcystin‐LR (MCLR), a cyclic heptapeptide hepatotoxin isolated from the cyanobacterium Microcystis aeruginosa, were produced. They showed the protective effects on hepatotoxicity of MCLR in vitro and in vivo, and on the inhibition of protein phosphatase by MCLR. Competitive enzyme‐linked immunosorbent assays with various microcystins revealed that the six MAbs recognized a part of the molecule, in particular, a tertial structure around Adda, 3‐amino‐9‐methoxy‐2,6,8‐trimethyl‐10‐phenyldeca‐4,6‐dienoic acid. The specificity of these MAbs varied slightly. In primary rat hepatocyte cultures, all MAbs showed protective effects against the MCLR‐induced cell damages, assessed by morphological changes, lactate dehydrogenase release into the medium, and a calorimetric assay to measure the cell viability using a tetrazolium dye. The M8H5 MAb showing the highest affinity for MCLR blocked the lethal effects and hepatocellular damage to mice. In addition, M8H5 MAb recovered protein phosphatase 2A inhibition by MCLR in a dose‐dependent manner, while phosphatase inhibition by okadaic acid was not affected. Thus, the MAbs specifically reacted with the microcystins and prevented their biological activities. This is the first report on the protective effects of specific monoclonal antibodies on MCLR‐induced toxicity. © 1995 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Nonneutralizing monoclonal antibodies were prepared against two strains, S2 and YO, of human rotaviruses isolated in cell culture. S2-37 and YO-5 antibodies had subgroup I and subgroup II specificities, respectively. The remaining antibodies (S2-65, YO-71, YO-89, and YO-156) reacted commonly with al